

CITATION REPORT

List of articles citing

Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial

DOI: 10.1161/circulationaha.116.022361
Circulation, 2016, 134, 24-36.

Source: <https://exaly.com/paper-pdf/64662352/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
210	Renal Function in Atrial Fibrillation: A Multifaceted Dilemma. <i>Circulation</i> , 2016 , 134, 48-51	16.7	8
209	What do the guidelines suggest for non-vitamin K antagonist oral anticoagulant use for stroke prevention in atrial fibrillation?. 2016 , 18, 118-124		2
208	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. 2016 , 68, 1169-1178		99
207	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. <i>Circulation</i> , 2016 , 134, 1122-1124	16.7	2
206	Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. 2017 , 34, 620-637		6
205	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. <i>Circulation</i> , 2017 , 135, 1001-1003	16.7	18
204	Renal Function Considerations for Stroke Prevention in Atrial Fibrillation. 2017 , 130, 1015-1023		25
203	Warfarin, Atrial Fibrillation, and CKD: Effective and Safe, but Soon Extinct?. 2017 , 69, 720-722		1
202	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. 2017 , 32, 1967-1976		11
201	Oral anticoagulant therapy for older patients with atrial fibrillation: a review of current evidence. 2017 , 41, 18-27		18
200	Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation. 2017 , 63, 152-164		51
199	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis. 2017 , 231, 162-169		54
198	Meta-analysis of safety and efficacy for direct oral anticoagulation treatment of non-valvular atrial fibrillation in relation to renal function. 2017 , 160, 41-50		26
197	Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation. 2017 , 34, 2274-2294		4
196	The safety of edoxaban for treating atrial fibrillation. 2017 , 16, 1295-1303		2
195	2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. 2017 , 33, 345-367		93
194	Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation. 2017 , 6, 549-560		4

193	The relationship of renal function to outcome: A post hoc analysis from the Edoxaban versus warfarin in subjects Undergoing cardioversion of Atrial Fibrillation (ENSURE-AF) study. 2017 , 193, 16-22	5
192	Recent Advances in Stroke Prevention in Patients with Atrial Fibrillation and End-Stage Renal Disease. 2017 , 7, 207-217	12
191	Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. 2017 , 11, CD011373	47
190	Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. 2017 , 11, 243-256	20
189	Drug therapy in anticoagulation: which drug for which patient?. 2017 , 17, 233-244	6
188	Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. 2017 , 13, 113-122	4
187	The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. 2017 , 10, 5-15	3
186	Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile. 2017 , 13, 49-64	0
185	DOAC use in patients with chronic kidney disease. 2017 , 37, 286-294	0
184	Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis. 2017 , 359-372	1
183	Direct Oral Anticoagulants: A Quick Guide. 2017 , 12, 40-45	47
182	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. 2018 , 39, 2314-2325	104
181	Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban. 2018 , 34, 1945-1957	2
180	State of play and future direction with NOACs: An expert consensus. 2018 , 106, 9-21	7
179	Direct Oral Anticoagulants in End-Stage Renal Disease. 2018 , 44, 353-363	12
178	Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. 2018 , 104, 301-310	11
177	Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists. 2018 , 60, 514-523	7
176	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. 2018 , 198, 169-177	6

175	Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation. 2018 , 33, 1683-1689	17
174	Non-Vitamin K-Dependent Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With CKD: Pragmatic Considerations for the Clinician. 2018 , 72, 717-727	10
173	Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants. 2018 , 151, 210.e1-210.e13	1
172	Fitting the right non-vitamin K antagonist oral anticoagulant to the right patient with non-valvular atrial fibrillation: an evidence-based choice. 2018 , 50, 288-302	10
171	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. 2018 , 14, 337-351	50
170	Novel oral anticoagulants in chronic kidney disease: ready for prime time?. 2018 , 27, 201-208	4
169	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. 2018 , 20, 1231-1242	148
168	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. 2018 , 39, 1330-1393	1094
167	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. 2018 , 121, 131-140	15
166	[New oral anticoagulants (NOAC) in stroke treatment]. 2018 , 86, 117-124	
165	Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study. 2018 , 27, 174-181	17
164	A Renal Function Based Trade-Off Analysis of Non-vitamin K Antagonist Oral Anticoagulants in Nonvalvular Atrial Fibrillation. 2018 , 9, 1644	4
163	Anticoagulantes orales no dependientes de la vitamina K para pacientes con fibrilaci3n auricular e insuficiencia renal grave. 2018 , 71, 847-855	13
162	Use of oral anticoagulants in complex clinical situations with atrial fibrillation. 2018 , 150 Suppl 1, 8-24	2
161	Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk. 2018 , 41, 1395-1402	13
160	Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants. 2018 , 151, 210.e1-210.e13	
159	Anticoagulation for Stroke Prevention in Older Adults with Atrial Fibrillation and Comorbidity: Current Evidence and Treatment Challenges. 2018 , 48, 873-889	7
158	Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants. 2018 , 93, 1503-1519	7

157	Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. 2018 , 12, 361-380	12
156	DOAC use in patients with chronic kidney disease. 2018 , 47, 146-154	1
155	Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation. 2018 , 49, 2421-2429	28
154	The use of direct oral anticoagulants in chronic kidney disease. 2018 , 183, 170-184	24
153	Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Renal Dysfunction. 2018 , 71, 847-855	3
152	Reducing age bias in decision analyses of anticoagulation for patients with nonvalvular atrial fibrillation - A microsimulation study. 2018 , 13, e0199593	2
151	Incident Atrial Fibrillation and the Risk of Stroke in Adults with Chronic Kidney Disease: The Stockholm CREATinine Measurements (SCREAM) Project. 2018 , 13, 1314-1320	25
150	Variability in Non-Vitamin K Antagonist Oral Anticoagulants Dose Adjustment in Atrial Fibrillation Patients With Renal Dysfunction: The Influence of Renal Function Estimation Formulae. 2018 , 34, 1010-1018	23
149	Oral Anticoagulation in Patients With Liver Disease. 2018 , 71, 2162-2175	83
148	Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). 2018 , 11, e003998	20
147	Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety. 2018 , 72, 838-853	67
146	Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding. 2018 , 130, 722-734	1
145	All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism. 2018 , 118, 1637-1645	9
144	Direct oral anticoagulants for stroke prevention in atrial fibrillation: treatment outcomes and dosing in special populations. 2018 , 12, 247-262	7
143	Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. 2019 , 14, 278-287	29
142	Anticoagulation in Patients With Advanced Chronic Kidney Disease: Walking the Fine Line Between Benefit and Harm. 2019 , 35, 1241-1255	5
141	Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. 2019 , 24, 499-508	1
140	Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease. 2019 , 15, 530-537	2

139	Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease. 2019 , 42, 1463-1470		5
138	Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week. 2019 , 74, 2204-2215		45
137	2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. <i>Circulation</i> 2019 , 140, e125-e151	16.7	1020
136	2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2019 , 16, e66-e93		176
135	2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2019 , 74, 104-132		807
134	Progress in the monitoring of direct oral anticoagulant therapy. 2019 , 184, 912-924		21
133	Optimizing Anticoagulation in Older Patients with Nonvalvular Atrial Fibrillation. 2019 , 13, 1		
132	Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management. 2019 , 18, 187-209		15
131	Renal function and oral anticoagulant treatment of incident non-valvular atrial fibrillation: a retrospective study. 2019 , 15, 301-309		4
130	Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019. 2019 , 33, 481-488		7
129	Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany - A retrospective cohort study. 2019 , 23, 100367		10
128	Oral anticoagulation in patients with chronic kidney disease: A systematic review and meta-analysis. 2019 , 92, e2421-e2431		23
127	Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function. 2019 , 50, 1480-1489		8
126	Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation. 2019 , 9, 6690		10
125	Edoxaban for the prevention of stroke in patients with atrial fibrillation. 2019 , 17, 319-330		6
124	New factor Xa inhibitors based on 1,2,3,4-tetrahydroquinoline developed by molecular modelling. 2019 , 89, 215-224		7
123	Consensus in cardiology on non-vitamin-K oral anticoagulants for patients with atrial fibrillation. 2019 , 35, 1571-1582		1
122	Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. 2019 , 4, 198-223		61

121	Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization. 2019 , 19, 525-539	5
120	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. 2019 , 8, e010510	24
119	Net clinical benefit of non-vitamin K antagonist oral anticoagulants in atrial fibrillation and chronic kidney disease: a trade-off analysis from four phase III clinical trials. 2019 , 9, 410-419	10
118	Recent evidence for direct oral anticoagulants in chronic kidney disease. 2019 , 28, 251-261	4
117	Net clinical benefit analysis of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: Protocol for a systematic review and meta-analysis. 2019 , 98, e16194	2
116	The impact of renal function on efficacy and safety of new oral anticoagulant in atrial fibrillation patients: A systemic review and meta-analysis. 2019 , 98, e18205	5
115	[Anticoagulation in patients with non-valvular atrial fibrillation (nvAF) and chronic kidney disease (CKD)]. 2019 , 144, 1642-1649	0
114	Estimating Renal Function in Drug Development: Time to Take the Fork in the Road. 2019 , 59, 159-167	13
113	Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. 2019 , 40, 1518-1527	34
112	Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. 2019 , 40, 1492-1500	31
111	Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation. 2019 , 49, 115-124	15
110	Outpatient Oral Anticoagulant Therapy. 2019 , 747-777	1
109	A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. 2019 , 34, 265-277	40
108	Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation. 2020 , 27, e270-e2852	
107	Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. 2020 , 6, 167-175	5
106	Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration. 2020 , 11, 1293	1
105	Optimizing prognosis in atrial fibrillation: A call to action in Portugal. 2020 ,	
104	Direct oral anticoagulants in chronic kidney disease: an update. 2020 , 29, 489-496	0

103	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. 2020 , 36, 1847-1948	82
102	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. 2020 , 18, 2126-2137	30
101	Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. 2020 , 9, e017155	4
100	Clinical Discussions in Antithrombotic Therapy Management in Patients With Atrial Fibrillation: A Delphi Consensus Panel. 2020 , 2, 641-651	3
99	Dose discordance of direct acting oral anticoagulants using different equations for estimating GFR: a literature review. 2020 , 13, 857-863	4
98	Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. 2020 , 13, e006511	1
97	Paciente con alto riesgo cardiovascular y fibrilaci3n auricular: papel del rivaroxab3n. 2020 , 20, 30-38	
96	Selecci3n del tratamiento anticoagulante 3timo para el paciente con fibrilaci3n auricular y diabetes o enfermedad renal cr3nica: papel del rivaroxab3n. 2020 , 20, 39-45	1
95	Direct oral anticoagulants across the heart failure spectrum: the precision medicine era. 2020 , 1	1
94	Time in Therapeutic Range for Dialysis Patients on Warfarin: Determination and the Effect of Dietary Intervention. 2020 , 95, 1206-1211	0
93	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. 2020 , 80, 1065-1083	13
92	Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. 2020 , 9, e017559	101
91	Antithrombotic treatment strategies after PCI. 2020 , 395, 866	
90	Pharmacological Review of Anticoagulants. 2020 ,	1
89	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. 2020 , 75, 1145-1155	19
88	Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation. 2020 , 51, 2364-2373	14
87	DARE to Prescribe: Strategy to Guide Direct Oral Anticoagulant Therapy. 2020 , 16, 509-513	2
86	Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry subanalysis. 2020 , 223, 23-33	5

85	Relationship between the Renal Function and Adverse Clinical Events in Patients with Atrial Fibrillation: A Japanese Multicenter Registry Substudy. 2020 , 9,	5
84	The Challenge of Untangling the Interdependencies Between Complications After Cardiac Surgery. 2020 , 34, 1791-1793	
83	Should we monitor the direct oral anticoagulants?. 2020 , 50, 30-32	4
82	Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. 2021 , 7, f30-f39	10
81	Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Societ�Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Societ�Italiana per lo Studio dell'Emostasi e della Trombosi (SISET). 2021 , 34, 31-38	3
80	Outcomes in VKA-treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs Real-worldR 2021 , 75, e13888	1
79	Oral anticoagulation in chronic kidney disease with atrial fibrillation. 2021 , 41, 137-153	0
78	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. 2021 , 13, 373-488	1676
77	Use of DOAC in Patients with Kidney Disease. 2021 , 121-130	
76	Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. 2021 ,	0
75	Use of Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention across the Stroke Spectrum: Progress and Prospects. 2021 , 121, 716-730	1
74	Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a systematic review. 2021 , 11, e042024	2
73	Analysis of the Introduction in Clinical Practice of New Oral Anticoagulants in Local Health Agency BT: Translation of the Clinical Trial Data to a Local Health Care Area. 2021 , 13,	1
72	Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney Disease or on Dialysis. 2021 , 35, 273-281	5
71	Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance. 2021 , 14,	0
70	Oral anticoagulation in chronic kidney disease with atrial fibrillation. 2021 , 41, 137-153	
69	Renal Disease and Atrial Fibrillation. 2021 , 13, 95-112	2
68	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2021 , 143, 1215-1223	16.7 1

67	Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis. 2021 , 41, 341-351	4
66	Comparison of the Safety and Efficacy of Direct Oral Anticoagulants and Warfarin in Atrial Fibrillation or Venous Thromboembolism in Patients with Renal Impairment: Systematic Review, Meta-Analysis and Network Meta-Analysis. 2021 , 21, 643-657	2
65	Oral Anticoagulant Agents in Patients With Atrial Fibrillation and CKD: A Systematic Review and Pairwise Network Meta-analysis. 2021 , 78, 678-689.e1	1
64	Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management. 2021 , 16, e23	6
63	Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation. 2021 , 38, 2891-2907	2
62	Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS). 2021 , 74, 437.e1-437.e116	3
61	[Interdisciplinary aspects of oral anticoagulation with NOACs in atrial fibrillation]. 2021 , 146, S2-S16	
60	The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation. 2021 , 5, e353-e362	2
59	Lead thrombus under standard-dose edoxaban in a patient with normal to high creatinine clearance and protein S deficiency. 2021 , 19, 50	2
58	Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity. 2021 , 43, e255-e263	2
57	Optimizing prognosis in atrial fibrillation: A call to action in Portugal. 2021 , 40, 595-605	
56	Edoxaban in cardiovascular disease management: Review. 2021 ,	0
55	2021 Korean Heart Rhythm Society Guidelines: Management of Atrial Fibrillation in Specific Clinical Settings. 2021 , 96, 264-295	
54	Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis. 2021 , 5, e12575	0
53	Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review. 2021 , 8, 654620	
52	Factors Associated With Edoxaban Concentration Among Patients With Atrial Fibrillation. 2021 , 12, 736826	
51	Antikoagulation bei chronisch nierenkranken Menschen mit Vorhofflimmern. 2021 , 25, 266-272	
50	Pharmacokinetics and Pharmacodynamics of DOAC. 2021 , 27-40	

49	[The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease]. 2018 , 107, 683-687	1
48	Direct-Acting Oral Anticoagulants in Atrial Fibrillation: What's New in the Literature. 2021 , 29, 120-130	2
47	Use of DOACs in real-world challenging settings: a Delphi Consensus from Italian cardiologists. 2019 , 67, 361-373	4
46	CHRONIC KIDNEY DISEASE AND ARRHYTHMIAS: CONCLUSIONS FROM A KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO) CONTROVERSIES CONFERENCE. 2019 , 23, 18-40	2
45	Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. 2020 , 10,	7
44	2018 KHRS Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Atrial Fibrillation: How to Initiate and Organize the Follow-up. 2019 , 94, 17-39	1
43	The Nonvitamin K Antagonist Oral Anticoagulants and Atrial Fibrillation: Challenges and Considerations. 2017 , 9, 1547	2
42	The use of anticoagulants in chronic kidney disease: Common point of view of cardiologists and nephrologists. 2020 , 27, 868-874	1
41	Defibrillation Testing During ICD Implantation - Should we or Should we Not?. 2017 , 9, 1508	1
40	Updates on Direct Oral Anticoagulants in the Management of Atrial Fibrillation. 2019 , 5, 24	
39	Recent Advances for Stroke Prevention in Patients With Atrial Fibrillation and Advanced Kidney Disease. 2019 , 736-740.e2	
38	CHOICE OF DIRECT ORAL ANTICOAGULANTS BASED ON THE INDIVIDUAL APPROACH. 2019 , 5, 10-22	
37	(Anticoagulation therapy in patients with chronic kidney disease). 2019 , 61, 599-605	0
36	[Direct Oral Anticoagulant Edoxaban in Patients with Non-Valvular Atrial Fibrillation: Results of Direct Comparison with Warfarin]. 2020 , 60, 124-129	1
35	The role of edoxaban in preventing thromboembolic complications in patients with atrial fibrillation. 2020 , 28-43	
34	New aspects of anticoagulant therapy in atrial fibrillation in patients with renal dysfunction. 2020 , 25, 4175	
33	Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. 2020 , 22, 078-086	5
32	[Comparative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease]. 2020 , 60, 102-109	

- 31 Anticoagulation for Atrial Fibrillation in Advanced Chronic Kidney Disease. **2021**, 333-341
- 30 Arrhythmias in Chronic Kidney Disease: Working Towards a Clinical Approach in Atrial Fibrillation. **2021**, 47-57
- 29 Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and Siset. **2020**, 18, 478-485
- 28 Mild Renal Dysfunction and Risk of Thromboembolism and Bleeding in Patients with Atrial Fibrillation: The Chinese Atrial Fibrillation Registry Study. **2021**, 1, 29-36
- 27 Edoxaban vs. Warfarin in High-risk Patients with Atrial Fibrillation: A Comprehensive Analysis of High-Risk Subgroups.. **2022**, ○
- 26 Prior direct oral anticoagulant dosage and outcomes in patients with acute ischemic stroke and non-valvular atrial fibrillation: A sub-analysis of PASTA registry study.. **2022**, 434, 120163 ○
- 25 Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases.. **2022**, 24, A11-A18
- 24 Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial.. *Circulation*, **2022**, 145, 718-720 16.7
- 23 Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min. **2021**, ○
- 22 DataSheet_1.doc. **2020**,
- 21 Table_1.DOCX. **2018**,
- 20 The use of non-vitamin K oral anticoagulants in dialysis patientsA systematic review.
- 19 Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. 9, ○
- 18 Direct Oral Anticoagulants for Anticoagulation after Initial Management of Venous Thromboembolism. **2022**, 20, 9-14
- 17 Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation.
- 16 Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.
- 15 A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease. ○
- 14 Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration?. ○

- 13 Stroke Prevention in Atrial Fibrillation. **2022,**
- 12 Effect of Atrial Fibrillation on Renal Function: Time of Change-Point Analysis of the Estimated Glomerular Filtration Rate Before and after Development of Atrial Fibrillation. ○
- 11 Impact of Renal Function on Anti-factor Xa Activity Concentrations with Edoxaban Use in Patients with Non-valvular Atrial Fibrillation. ○
- 10 Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis. 9, ○
- 9 The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function: A systematic review. **2022,** 107123 ○
- 8 Association of Kidney Function With Risk of Adverse Effects of Therapies for Atrial Fibrillation. **2022,** ○
- 7 Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with Direct Oral Anticoagulants. **2022,** 17, e0278693 ○
- 6 Oral Anticoagulation in Patients with Chronic Kidney Disease and Non-Valvular Atrial Fibrillation: The FAERC Study. **2022,** 10, 2566 ○
- 5 Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis. **2023,** 10, 13 ○
- 4 Anticoagulation in Elderly Patients With Atrial Fibrillation and Renal Dysfunction. **2023,** ○
- 3 Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. **2023,** 54, ○
- 2 Atrial fibrillation: Primary prevention, secondary prevention, and prevention of thromboembolic complications: Part 2. 9, ○
- 1 Renal Function and Clinical Outcomes Among Elderly Patients With Nonvalvular Atrial Fibrillation From ANAFIE. **2023,** ○